Sirius-biotech has acquired from the National Cancer Institute of Genoa a novel anti-periostin antibody, OC-20, that shows inhibitory effects on tumor growth and angiogenesis in vivo in tumor-bearing mice. OC-20 reacts with an epitope localised in the second FAS1 domain (FAS1-2) of periostin. This epitope is a new cell binding site of perostin, interacting with the […]
Bone reconstruction evidence after tissue engineering study